Regulatory approval

Published by the Health Service Executive. Approved

Treatment of adult patients with breast cancer, whose tumours overexpress HER2 in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which should have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting.

This is written in the approval document.

Reimbursement

CDS

Citation

Lapatinib and Capecitabine Therapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 26/03/2026, https://healthservice.hse.ie/documents/6559/217_v6b_Lapatinib_Capecitabine_therapy.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Capecitabine, Lapatinib
HSE (1)	ERBB2 amplification	Invasive Breast Carcinoma	Capecitabine, Lapatinib

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2015-01-10	Health Service Executive	Indication approved for reimbursement.